- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Zevalin Used in Auto Stem Cell Transplant Effective for Chemo Resistant Aggressive NHL
Zevalin is a combination of Rituxan attached to the isotope Yttrium 90. The US Food and Drug Administration (FDA) has approved Zevalin for the treatment of patients with low-grade NHL that has stopped responding to standard therapies. The approval indicates that Zevalin must be used in combination with Rituxan®.
The trial presented at ASCO included 20 patients with a median age of 55 years whos NHL had become resistant to prior chemotherapy, with a median 3 prior regimens. NHL subtypes included mantle cell NHL, diffuse large cell and transformed follicular NHL.
14 patients achieved complete response (CR) and 4 achieved a partial response (PR). Estimated one-year survival is nearly 60%. Estimated one-year progression-free survival is 53%. The day 100 treatment-related mortality was 10%.
The researchers concluded that the inclusion of Zevalin into high-dose chemotherapy regimens may improve disease-free survival and overall survival compared to high-dose chemotherapy and stem cell transplantation alone in patients with refractory, aggressive NHL. ASCO.org